/stocks — the workspaceLOADING
Eli Lilly makes tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, the drugs behind its recent revenue surge. Its portfolio also includes the breast cancer drug Verzenio, Alzheimer's treatment Kisunla, and a large insulin business.
ELI LILLY & Co (LLY) is a pharmaceutical preparations company. Piotroski F-Score 5/7. 14 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-06 from LLY's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Led by David Ricks · see pay & career →
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
A plain-English read on LLY plus an auto-SWOT — built from LLY's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate LLY using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Yuffa IlyaEVP&Pres, LLY USA&Global Capab | SELL | $2.9M | view → |
| LILLY ENDOWMENT INCInsider | SELL | $15.8M | view → |
| Rohit KhannaU.S. Representative · CA-17 | BUY | $1,001 - $15,000 | filed 2026-07-06 |
| Gilbert CisnerosU.S. Representative · CA-39 | BUY | $50,001 - $100,000 | filed 2026-07-02 |
| Fisher Asset Management (Ken Fisher) | $4.45B | 1.5% of portfolio |
Projected from LLY's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment LLY files its announcement.
LLY's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Large earnings reactions have been common.
The average is inflated by its most volatile prints (+13.2% and -16.2%).
A more typical earnings reaction has been approximately ±7.3%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-30 | +13.2% |
| 2026-02-04 | +1.7% |
| 2025-10-30 | +6.1% |
| 2025-08-07 | -16.2% |
| 2025-05-01 | -8.4% |
| 2025-02-06 | +4.3% |
| 2025-01-14 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -6.4% |
| 2024-10-30 | -8.2% |